Home Overview Press Room Blog Publications For Students about us

Personal genomics : Displaying 200-219 of 532

Fetal Genome Screening Could Prove TragicScientific AmericanJanuary 18th, 2013Parents will soon be able to have their fetus' genes mapped. Without proper guidance, they might decide to end the pregnancy based on a misguided reading of the genetic tea leaves.
It's Legal For Some Insurers To Discriminate Based On Genesby David SchultzNPRJanuary 17th, 2013The Genetic Information Nondiscrimination Act has a loophole: It only applies to health insurance. It says nothing about life insurance, disability insurance or long-term-care insurance.
Born to Run the World?by Abby Lippman, Biopolitical Times guest contributorBiopolitical TimesJanuary 17th, 2013Forget about glass ceilings, sexism in employment, gender inequities, and all those other structural and societal policies and practices that put obstacles in the way of women (and racialized groups) getting ahead. Maybe they just lack the "leadership gene."
The Case for Paternalism in Genetic Testingby Laura HercherWiredJanuary 14th, 2013In light of recent articles arguing for more openness and less worry about people receiving their genomic information, one genetic counselor explains why she cannot participate in the full-throated enthusiasm.
Your Medical Data in the Cloud? Not So Fast, Says HHS Privacy Officialby Andrea PetersonScience ProgressJanuary 9th, 2013Digital health records are superior to physical ones for many reasons, but data security and privacy of health information are major obstacles and policy has not yet caught up with practice.
No Easy Answer[Editorial]NatureJanuary 9th, 2013Demands to analyse the DNA of the Connecticut school shooter are misguided and could lead to dangerous stigmatization, or worse.
Follow the Biotech Money … If You Can Find It by Pete ShanksBiopolitical TimesJanuary 9th, 2013In a relatively slow period for mergers and acquisitions in genomics and related sectors, Illumina, Amgen, BGI, and BioTime were buyers and 23andMe added financing while Geron sold and Roche held off.
Seeking Answers in Genome of Gunmanby Gina KolataNew York TimesDecember 24th, 2012In a move likely to renew a longstanding ethical controversy, geneticists are quietly making plans to study the DNA of the man who killed 20 children and seven adults in Newtown, Connecticut.
Year of the Fetusby Beth Marie MoleThe ScientistDecember 18th, 20122012 saw the introduction of a handful of non-invasive genetic prenatal tests, but the young industry faces growing pains as legal and ethical questions loom.
Direct-to-Consumer Genetic Testing: The Dollars are in the Database by Emily StehrBiopolitical TimesDecember 18th, 201223andMe raised $50 million and plans to use it to lower the cost of its spit kit to $99. CEO Anne Wojcicki hopes this will lead to a very valuable database of one million users' genetic information.
DeliriousMe: Ownership and Identity in An Age of Genomic Medicineby Patricia WilliamsLOG: Journal of Architecture and UrbanismDecember 17th, 2012The question of who owns our bodies — in particular the genomic information that may be culled from routine human shedding — is a matter of evolving legal, social and ethical importance.
Review: Bioethics: All That Matters by Donna Dickensonby Gina Maranto, Biopolitical Times guest contributorDecember 13th, 2012This lively and accessible guide to the ethical implications of biotechnology asks how the field promotes or undermines social equality.
Genes, Patents, and Big Business: at 23andMe, are you the Customer or the Product?Ethical questions swirl as the personal genetics company starts scaling upby Adrianne JeffriesThe VergeDecember 12th, 201223andMe has raised $50 million from investors and decisively shifted its focus to building and monetizing a giant database of genetic information, rather than satisfying personal curiosity.
Why Your DNA is a Goldmine for Marketers[Quotes CGS's Marcy Darnovsky]by Carolyn AbrahamThe Globe and MailDecember 12th, 2012In the ever-growing field of personal-data mining, marketing firms already latch on to details far beyond the sphere of names and postal codes; DNA may well be the next frontier.
Non-Invasive Prenatal Testing: Is This the Brave New World We Want?by Alexandra Minna SternThe Huffington PostDecember 11th, 2012Several companies have recently unveiled non-invasive prenatal tests for use among "high-risk" women, but the history of prenatal testing in America suggests that a path to routinization is all but assured.
Genome Challenge Emerges in Society Sharing DNA Benefitsby John LauermanBloomberg BusinessweekDecember 9th, 2012Scientists at a Nobel conference in Stockholm voiced worry that we will end up with a genetic divide, increasing already problematic social inequalities.
New Business Plans for the Direct-to-Consumer Gene Testing Industry? by Pete ShanksBiopolitical TimesDecember 9th, 2012The direct-to-consumer gene testing industry is still evolving, and searching for ways to profit.
Expert Tours His Own Exome, and Finds Mainly False Alarmsby Monya BakerNatureDecember 6th, 2012A DNA expert jumped at the chance to have his exome sequenced, but after extensive analysis, found that almost none of the reported variants meant anything useful.
Genome Sequencing For Babies Brings Knowledge And Conflictsby Rob SteinNPRDecember 3rd, 2012Sequencing an individual's genome at birth would enable doctors to screen for far more genetic conditions than they do now, but what do parents do with all the information?
The Value of Your GenomeGenome sequencing: it’s not for everyoneby James P. Evans and Jonathan S. BergThe ScientistDecember 1st, 2012Whole genome sequencing is unlikely to become a routine part of medicine anytime soon.
Displaying 200-219 of 532  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1936 University Ave, Suite 350, Berkeley, CA 94704 • • (p) 1.510.665.7760 • (F) 1.510.665.8760